Christopher Haqq
2022 - Elicio Therapeutics
In 2022, Christopher Haqq earned a total compensation of $1.2M as Executive Vice President, Head of Research and Development and Chief Medical Officer at Elicio Therapeutics.
Compensation breakdown
Non-Equity Incentive Plan | $186,010 |
---|---|
Option Awards | $511,321 |
Salary | $465,025 |
Total | $1,162,356 |
Haqq received $511.3K in option awards, accounting for 44% of the total pay in 2022.
Haqq also received $186K in non-equity incentive plan and $465K in salary.
Rankings
In 2022, Christopher Haqq's compensation ranked 2,745th out of 5,736 executives tracked by ExecPay. In other words, Haqq earned more than 52.1% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,745 | 52nd |
Manufacturing | 1,527 | 51st |
Chemicals And Allied Products | 706 | 50th |
Drugs | 658 | 50th |
Pharmaceutical Preparations | 475 | 51st |
Haqq's colleagues
We found three more compensation records of executives who worked with Christopher Haqq at Elicio Therapeutics in 2022.